Durham, NC, United States of America

Roseanne Gerding


 

Average Co-Inventor Count = 14.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2011

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Roseanne Gerding

Introduction

Roseanne Gerding is a notable inventor based in Durham, NC (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target cancer treatment. Her work has led to the creation of a patent that showcases her innovative approach to medical science.

Latest Patents

Roseanne Gerding holds a patent for her invention titled "2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer." This patent includes novel pyrrolopyrimidines and their pharmaceutically acceptable derivatives. The compounds developed by Gerding are particularly useful in the inhibition of IGF-1R, which plays a crucial role in cancer progression.

Career Highlights

Throughout her career, Roseanne has worked with prominent companies in the pharmaceutical industry. Notably, she has been associated with GlaxoSmithKline LLC and GlaxoSmithKline Intellectual Property Development Limited. Her experience in these organizations has allowed her to contribute to groundbreaking research and development in cancer therapies.

Collaborations

Roseanne Gerding has collaborated with esteemed colleagues, including Stanley Dawes Chamberlain and Felix Deanda, Jr. These partnerships have further enhanced her research capabilities and have led to advancements in her field.

Conclusion

In summary, Roseanne Gerding is a pioneering inventor whose work in cancer treatment has made a significant impact. Her patent and collaborations reflect her dedication to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…